论文部分内容阅读
目的观察阿托伐他汀强化治疗能否减少造影剂对肾功能的影响和减少对比剂肾病(CIN)的发病率。方法选取行冠心病介入治疗(PCI)术患者80名,随机分为强化治疗组(给予阿托伐他汀40 mg·d~(-1))和常规治疗组即对照组(阿托伐他汀20mg·d~(-1)),观察2组患者(PCI)术前术后肾功能情况并作统计学处理。结果 80例患者发生CIN 15例,其中治疗组5例(12.5%),对照组10例(25%)。治疗组术后各项指标与术前比较差异无统计学意义,对照组术后尿素氮、肌酐、肌酐清除率、肾小球滤过率与术前比较差异均有统计学意义(P<0.05)。结论阿托伐他汀强化治疗有着心血管保护作用之外的肾脏保护作用,对于拟行PCI术的冠心病患者合并肾功能异常时,术前1周给予阿托伐他汀强化治疗,术后给予充分的水化治疗,可减少CIN的发病率及减少造影剂对肾功能的损害。
Objective To investigate whether atorvastatin can reduce the effect of contrast media on renal function and reduce the incidence of contrast-induced nephropathy (CIN). Methods Eighty patients undergoing PCI were randomly divided into intensive treatment group (given atorvastatin 40 mg · d ~ (-1)) and control group (atorvastatin 20 mg · D ~ (-1)). The renal function of two groups of patients (PCI) before and after surgery were observed and statistically analyzed. Results 80 patients developed CIN in 15 cases, including 5 cases (12.5%) in the treatment group and 10 cases (25%) in the control group. There were no significant differences between the two groups in the postoperative indexes of the treatment group and the preoperative values. The postoperative urea nitrogen, creatinine, creatinine clearance rate, glomerular filtration rate in the control group were significantly different from those before operation (P <0.05 ). Conclusions Atorvastatin has a protective effect of cardiovascular protection in addition to cardiovascular protection. For those patients with coronary artery disease undergoing PCI, patients with renal dysfunction should be treated with atorvastatin for 1 week before operation and adequate after operation Hydration therapy can reduce the incidence of CIN and reduce the contrast agent on renal function damage.